Yao Yun has filed an amendment to a previous Schedule 13D, reporting a decrease in her beneficial ownership of Indaptus Therapeutics, Inc. This filing is significant as it highlights shifts in ownership stakes within the pharmaceutical preparations sector.
Yao Yun, an individual investor based in Australia, is the owner of 41,991,000 shares of Indaptus Therapeutics, which equates to 27.34% of the company's common stock. This decrease in ownership percentage is attributed to the issuance of new shares during a recent private placement, which has expanded the total number of outstanding shares.
Background
Indaptus Therapeutics, Inc. is a Delaware corporation primarily engaged in pharmaceutical preparations. The company is listed under the Central Index Key (CIK) 0001857044. Yao Yun, identified as a private investor, has been actively involved in the company’s equity transactions, as evidenced by her previous filings.
What the Filing Says
The recent filing, dated October 22, 2026, indicates that Yun's ownership has decreased due to the issuance of 20,338,974 shares of common stock in connection with a private placement on October 16, 2026. The filing states, "This Amendment No. 3 is being filed to report a decrease of more than 1% in the percentage of the outstanding Common Stock beneficially owned by the Reporting Person." Yun did not acquire or dispose of shares during this period.
Impact
This change in ownership may affect the dynamics of shareholder influence within Indaptus Therapeutics. With Yun still holding a significant stake, her decisions and opinions may continue to play a crucial role in the company's strategic direction. The pharmaceutical preparations industry may also observe this shift as a reflection of broader trends in investor behavior and stock issuance practices.
What's Next
The filing does not say what happens next regarding Yun's ownership or any further actions she may take. However, the company’s ongoing developments and future filings will likely provide more insights into the evolving landscape of ownership and investment in Indaptus Therapeutics.